

# Mapping Cancer Stem Cell Markers Distribution: A Hypergraph Analysis Across Organs

David H. Margarit<sup>1,3,\*</sup>, Gustavo Paccosi<sup>2</sup>, Marcela V. Reale<sup>1,3,4</sup>,  
and Lilia M. Romanelli<sup>1,3</sup>

<sup>1</sup> Instituto de Ciencias - Universidad Nacional de General Sarmiento (UNGS), J. M. Gutiérrez 1150, Los Polvorines (B1613), Buenos Aires, Argentina.

<sup>2</sup> Instituto de Desarrollo Humano - Universidad Nacional de General Sarmiento (UNGS), J. M. Gutiérrez 1150, Los Polvorines (B1613), Buenos Aires, Argentina.

<sup>3</sup> Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

<sup>4</sup> Departamento de Ingeniería e Investigaciones Tecnológicas - Universidad Nacional de La Matanza (UNLaM), Florencio Varela 1903, San Justo (B1754), Buenos Aires, Argentina.

\*Corresponding author: dmargarit@campus.ungs.edu.ar

*Keywords:* Hypergraphs, Biological Modelling, Cancer Stem Cell Markers, Cancer Progression.

**Abstract.** This study presents an interdisciplinary approach to analyse the distribution of cancer stem cell markers (CSCMs) across various cancer-affected organs using hypergraphs. Cancer stem cells (CSCs) play a crucial role in cancer initiation, progression, and metastasis. By employing hypergraphs, we model the relationships between CSCM locations and cancerous organs, providing a comprehensive representation of these interactions. Initially, we utilised an unweighted incidence matrix and its Markov transition matrices to gain a dynamic perspective on CSCM distributions. This method allows us to observe how these markers spread and influence cancer progression in a dynamical context. By calculating mutual information for each node and hyperedge, our analysis uncovers complex interaction patterns between CSCMs and organs, highlighting the critical roles of certain markers in cancer progression and metastasis. Our approach offers a detailed representation of cancer stem cell networks, enhancing our understanding of the mechanisms driving cancer heterogeneity and metastasis. By integrating hypergraph theory with cancer biology, this study provides valuable insights for developing targeted cancer therapies.

## 1. Introduction

Cancer modelling has emerged as a fundamental tool for identifying, diagnosing, and treating cancer across its various stages. These models leverage both *in vivo* and *in vitro* experimental data to create simulations that are increasingly realistic and applicable to modern therapies, which require constant refinement [1, 2]. Cancer originates when cells within healthy tissues undergo uncontrolled mitosis and apoptosis, resulting in the

abnormal accumulation of cells known as tumours. These cancer cells lose their original tissue functions, causing significant damage [3]. If left untreated, cancer can become vascularized and spread cancer cells through the blood or lymphatic system to other organs, where they establish new tumour processes known as metastasis [3, 4].

In the same way that there is a type of normal cell with the capacity to develop tissue, there is also a type of cancer cell capable of initiating the development of a tumour [5]. This type of cells, which can also self-renew and divide, are called stem cells (SC). In the context of cancer, also called malignant tumour, SCs are called Cancer Stem Cells (CSC) [6]. SCs constitute a subpopulation capable of indefinite self-renewal and differentiation, playing critical roles in cancer progression, recurrence, metastasis, and resistance to treatment [6].

Distinctive macromolecules, called markers, appear on the surfaces of CSCs when cancer originates in a specific organ [7, 8]. These markers vary and can manifest in one or more types of cancer. For example, markers such as *CD44+* and *CD133+* are found in multiple cancers such as breast, lung, and pancreas [8]. The study of cancer stem cell markers (CSCM) is crucial due to their implications in key aspects of cancer progression. These markers are related to resistance to chemotherapy and radiotherapy, contributing to cancer relapse and metastasis by allowing the survival of cells targeted by conventional treatments [9, 10]. Furthermore, they promote tumour heterogeneity, which complicates treatment by presenting several cellular subpopulations within the same tumour, each with different characteristics and resistant properties [11]. Developing therapies targeting these cells is crucial to prevent cancer recurrence and improve the effectiveness of treatment [12]. CSCMs also exhibit remarkable plasticity, adapting and surviving in diverse tumour environments, posing challenges to current therapies while offering opportunities to design strategies to hinder their plasticity and impede tumour progression [12].

The presence of common markers in different cancers highlights the complexity of these systems, requiring advanced analytical tools such as graph theory, in particular hypergraphs. Hypergraphs outperform traditional graphs by allowing the representation of complex multi-link relationships [13], making them suitable for characterizing and analysing biological networks such as cancer marker networks [7, 8, 14]. By modelling these interactions, we gain deeper insights into cancer dynamics and potentially identify new therapeutic pathways [7, 14]. Hypergraph theory is especially valuable in biology and medicine [15, 16, 17], as it allows modelling multivalent interactions that simple graphs cannot adequately capture. For example, hypergraphs have been used to model protein interaction networks, where hyperedges represent protein complexes involving multiple proteins simultaneously [18]. This approach has proven to be beneficial not only in cancer research but also in the study of other complex diseases, demonstrating its versatility and analytical prowess [19].

This article is organized as follows: The Section 2 provides a detailed introduction to the application of hypergraphs in the analysis of CSCM distribution in organs affected by cancer, laying the foundation for subsequent analyses. The Section 3 examines

Markovian transition processes between organs and CSCM, probabilistically elucidating possible metastatic relationships. The Section 4 explores the mutual information between nodes and hyperedges, shedding light on their interrelationships from this perspective. Finally, Section 5 summarizes the findings of this study and outlines future directions.

## 2. General objectives and methodology


The main objective of this work is to comprehensively analyse and characterize the distribution of various types of CSCMs within cancer tissues and organs using hypergraph theory. This analysis is essential to gain insights into tumour heterogeneity and the dynamics of cancer stem cell populations, which are critical to advancing more effective and personalized cancer therapies. This analysis is based on previous studies, in particular the complete data set compiled by Yang et al. (2020) [20], which classifies different CSCM subtypes in various cancer tissue samples. This research [20] is widely considered a key reference in the study of CSCMs and their impact on organs affected by cancer. Known for their comprehensive exploration of molecular pathways and resistance mechanisms in cancer stem cells, the work of Yang et al. provides a solid foundation for understanding tumour heterogeneity. The insights from this article are particularly valuable for hypergraph studies examining the distribution of cellular markers in different cancer types.

To implement this approach, each cancerous organ is treated as a node or vertex, while CSCM present in two or more organs are depicted as hyperedges connecting these nodes. Specifically, Yang et al. (2020) [20] underscore scenarios where various types of CSCMs associate with two or multiple organs, indicating inherent relationships that surpass the representation capabilities of conventional graphs, which connect only two nodes. To address this complexity, hypergraph theory is employed, offering a more robust framework to capture and analyse the intricate structure and interrelationships among CSCMs and affected organs.

Formally, a hypergraph is represented by an incidence matrix  $H = (V, E)$  [21], where  $V = \{v_1, \dots, v_N\}$  denotes the set of nodes (representing cancerous organs), and  $E = \{e_1, \dots, e_M\}$  denotes the set of hyperedges (representing connections involving one or more types of CSCM within specific affected organs). Each element  $H_{ij}$  of the matrix takes the value 1 if the vertex  $v_i$  is part of the hyperedge  $e_j$ , and 0 otherwise.

$$H_{ij} = \begin{cases} 1 & \text{if } v_i \in e_j \\ 0 & \text{if } v_i \notin e_j \end{cases} \quad (1)$$

In our study, we consider 23 organs and 16 CSCMs. Therefore, the incidence matrix  $H$  has considerable dimensions ( $23 \times 16$ ) to show it in the body of this work. So, it is represented in Eq. A.1 of Appendix A.1. However, it is clearly shown in Fig. 1. This study particularly focuses on cases in which identical types of CSCMs are identified in at least two different organs, as documented in the review by Yang et al. (2020)



**Figure 1.** Representation of the incidence matrix  $H$ . Each point indicates the node-hyperedge (organ-CSCM) interconnection.

[20]. The goal is to discern patterns and relationships between these markers that consistently manifest in multiple affected organs. This approach not only enhances our understanding of the biological underpinnings of these markers but also opens avenues for developing effective targeted therapies against multiple cancer types. In the following section, we will delve deeper into the properties of the hypergraph, illustrating how this visualization captures the system's complexity.

For space considerations, some types of cancer are written with their initials. *AML* stands for Acute Myeloid Leukemia, *HNSCC* for Head and Neck Squamous Cell Carcinoma, *RCC* for Renal Cell Carcinoma, *OSCC* for Oral Squamous Cell Carcinoma, and *CsCC* for cutaneous squamous cell carcinoma.

The set of vertices  $V$  and hyperedges  $E$  are, respectively:

$$V = \{v_1, \dots, v_{23}\} = \{\text{Breast, Prostate, Brain, Stomach, Colorectal, Liver, AML, Melanoma, Bladder, Ovarian, Pancreas, HNSCC, GallBlader, RCC, Lung, Mesothelioma, OSCC, cSCC, Esophageal, Myeloma, Cervix, Nasopharyngeal, Laryngeal}\}$$

$$E = \{e_1, \dots, e_{16}\} = \{CD90+, CD49f+, CD133+, ALDH+, CD117+, EpCAM+, CXCR4+, CD44+, CD71+, CD24+, CD206+, CD166+, CD20+, CD19+, ABCG2+\}$$

### 2.1. Brief characterization of hypergraph $H$

The matrix representation can be used to display the connections of all elements of  $H$ , facilitating structural analysis and understanding of interactions within the hypergraph. The diagonal matrix  $D_v$  (Eq. 2) represents the degrees of the vertices, which in this case correspond to the organs affected by cancer, indicating how many hyperedges contain that vertex [21, 13]. This degree provides crucial information about the centrality and connectivity of each organ within the hypergraph, helping to identify organs that frequently participate in interactions with multiple CSCMs.

$$D_v = \text{diag}(D_{v_{1,1}}, \dots, D_{v_{23,23}}) = (4, 6, 4, 8, 7, 6, 5, 3, 2, 6, 7, 3, 2, 4, 5, 1, 2, 2, 5, 1, 4, 4, 3)(2)$$

On the other hand, the diagonal matrix  $D_e$  (Eq. 3) represents the degrees of the hyperedges, indicating how many vertices are connected by that hyperedge [21, 13]. This degree is fundamental for understanding the extent of the interactions, and can reveal patterns of co-expression or co-occurrence of CSCMs among different organs.

$$D_e = \text{diag}(D_{e_{1,1}}, \dots, D_{e_{16,16}}) = (7, 5, 17, 15, 2, 6, 3, 18, 2, 6, 2, 3, 2, 2, 2, 2)(3)$$

Examining these matrices reveals important patterns and relationships between organs and CSCMs, enhancing our understanding of their distribution and interactions in cancer. Eq. 2 shows that organ degrees vary from 1 to 8, with the *Stomach* having the highest degree. For CSCMs (Eq. 3), degrees range from 2 to 18, with *ALDH+*, *CD133+*, and *CD44+* standing out with degrees of 15, 17, and 18, respectively. To mention two examples, the node/organ *AML* has a degree of 5 due to its inclusion in *CD19+*, *CD20+*, *CD44+*, *CD71+*, and *CD90+*, while the hyperedge/CSCM *CD166+* has a degree of 3, covering *Colorectal*, *HNSCC*, and *Lung*. This quantitative assessment highlights organ and marker connectivity within the hypergraph, providing a basis to explore CSCM functions and interactions in various cancer types.

On the other hand, the order ( $\mathcal{O}_H$ ) of the hypergraph is defined by the number of vertices it contains, i.e., the cardinality of  $V$ . In this case, observing that the hypergraph  $H$  consists of 23 vertices, we have:

$$\mathcal{O}_H = 23 \tag{4}$$

The order of the hypergraph is a fundamental measure that gives us an idea of the scale of the system we are analysing, indicating how many basic elements (vertices) participate in the interactions described by the hypergraph. Likewise, it is possible to define the size of  $H$ , denoted by  $\mathcal{T}_H$ . This is given by the cardinality of  $E$ , i.e., the number of hyperedges:

$$\mathcal{T}_H = 16 \tag{5}$$

The size of the hypergraph denotes the number of complex interactions, represented as hyperedges, present within the system. This metric is pivotal for gauging the density and intricacy of relationships among the vertices. Similarly, the rank ( $\mathcal{R}_H$ )

and co-rank ( $co\mathcal{R}_H$ ) of  $H$  are defined, which correspond to the size of the largest and smallest hyperedge, respectively. These metrics provide a more detailed insight into the distribution of the size of the hyperedges:

$$\mathcal{R}_H = 17 \tag{6}$$

$$co\mathcal{R}_H = 2 \tag{7}$$

The rank of the hypergraph indicates the number of vertices in the largest hyperedge, while the co-rank denotes the smallest hyperedge. Since  $\mathcal{R}_H \neq co\mathcal{R}_H$  (hyperedges have different cardinalities), the hypergraph is not *r-uniform*; and, due to the non-homogeneous cardinality of nodes, it is also not  *$\delta$ -uniform*. These *non-uniformities* highlight the diversity and heterogeneity of hypergraph  $H$ , suggesting that the interactions between vertices (organs affected by cancer) and hyperedges (CSCMs) vary considerably in complexity and frequency [13].

### 3. From hypergraph structures to Markovian processes

#### 3.1. Transition Matrices

A detailed analysis using Markovian concepts allows a precise examination of the transition matrices derived from a hypergraph. This approach facilitates modelling the dynamic connections within the hypergraph using Markov chains, which are robust mathematical tools for analysing systems where transition probabilities between states are crucial [22].

Transition matrices are essential for elucidating how relationships between nodes and hyperedges evolve over time. By rigorously analysing these matrices, latent structural patterns within the hypergraph can be discovered, providing insights into the possible evolution of interactions in subsequent iterations of the system. This capability has particular relevance in biological and medical contexts, where understanding the dynamics of interactions is essential to understand disease progression and optimize treatment strategies.

These matrices manifest in various forms depending on the transitions they encapsulate. For example, a transition matrix can detail the transition probability of a node (organ) to a hyperedge (CSCM), thus indicating the probability that an organ is associated with a specific cellular marker. Rather, it can represent the reverse transition, from a hyperedge to a node, revealing how a marker can be linked between different organs.

Of specific interest is the transition matrix that delineates the relationships between nodes. This matrix provides information about indirect connections between organs through pathways involving multiple hyperedges within the hypergraph. This aspect is particularly compelling since it approximates a Markovian transition matrix [23, 21]. In classical terms, a Markov transition matrix defines the probabilities of moving from one state to another in a single step. Applied within our hypergraph framework, it

facilitates modelling the probability that one cancer-affected organ indirectly influences another through its associations with various markers.

To achieve this, we define the transition probability  $p_{ve}$  from a specific vertex to a specific hyperedge. Generalizing this probability across all organs and cell markers, we construct the transition matrix  $P_{ve}$  as follows [23, 21]:

$$P_{ve} = D_v^{-1}H \quad (8)$$

Similarly, the transition probability  $p_{ev}$  from a hyperedge to a specific vertex is generalized as  $P_{ev}$ , the corresponding transition matrix, defined as [23, 21]:

$$P_{ev} = D_e^{-1}H^T \quad (9)$$

These matrices satisfy the following properties:

$$\sum_{e \in E} p_{ve} = 1 \quad \forall v \in V \quad \text{y} \quad \sum_{v \in V} p_{ev} = 1 \quad \forall e \in E$$


These properties ensure that the transition matrices are correctly normalized, meaning that the transition probabilities from a row, either from a vertex or hyperedge, or from a hyperedge to vertices, sum to 1. This is crucial for the analysis of Markovian systems, where probability conservation must be upheld [22].

We can calculate the matrix to study transitions from one organ to another organ  $p_{vv}$  (vertex-vertex) through the matrix  $P_{vv}$  [21]:

$$P_{vv} = \underbrace{D_v^{-1}H}_{P_{ve}} \underbrace{D_e^{-1}H^T}_{P_{ev}} = P_{ve}P_{ev} \quad (10)$$

Fig. 2 graphically represents the transition matrix  $P_{vv}$  between organs according to the hypergraph  $H$  using a heat map, showing the transition probabilities from one organ to another as a function of the distribution initial of the cancer stem. Cell markers (CSCM). This matrix  $P_{vv}$ , which is a transition matrix as known in Markov Chains [22], allows us to identify possible routes of cancer spread between different organs, which is crucial to understand the dynamics of metastasis in cancer. Because the matrix  $P_{vv}$  has considerable dimensions to include in the body of this work, it is represented in Eq. A.2 from Appendix A.2. Among the organs with cancer observed in the matrix  $P_{vv}$ , three depend exclusively on the sex of the person: *Prostate* (only for males) and *Ovarian* and *Cervix* (only for females). Therefore, the transition probabilities  $p_{vv}$  from *Prostate* to *Ovarian* or *Cervix*, and vice versa, should not be considered, as they have no biological meaning.

Based on Fig. 2, which accurately and clearly represents the matrix  $P_{vv}$ , we will carry out a detailed analysis of it. A first observation reveals that the diagonal (which relates an organ or node to itself) concentrates the main transitions between organs. This is because, generally, the first metastasis occurs in the adjacent tissue that makes up the same organ [24]. Recent studies have identified that the markers *EpCAM+* and *CD90+* are associated with oncogenic characteristics in hepatocellular carcinoma,



**Figure 2.** Representation of the transition matrix  $P_{vv}$  between organs for the hypergraph  $H$ .


highlighting the correlation between *EpCAM+* and advanced tumour stages, as well as between *CD90+* and a high probability of metastasis and treatment resistance [24].

In particular, *AML* and *Myeloma* have the highest probability of this occurring. On the other hand, there are three organs with a high probability of being the destination of metastasis: *Stomach*, *Colorectal* and *Liver*. These organs share areas of high probability of transition. This result is crucial because it indicates that the markers *CD49+*, *CD90+*, *CD133+* and *EpCAM+*, although they are not exclusively predominant in the three mentioned organs, significantly influence them [?].

Another result that we can extract is that the *Prostate*, *Ovarian*, *Pancreas* and *Lung* organs, although to a lesser extent than those previously mentioned, are also likely to harbour a new cancer. The marker *ALDH+* stands out, present in all the types of cancer mentioned, which again provides valuable information and alerts about the presence of this marker at the time of diagnosis, indicating in advance the possibility of generating new cancers if present (metastasis) [25].

In general, the biological meaning extracted from Eq. 10 lies in its ability to offer a novel perspective on metastasis pathways, based on the predominant distribution of cellular markers in different types of cancer. This information can help identify the organs most susceptible to cancer spread and the cancer stem cell markers (CSCM) most relevant in this process. Furthermore, taking advantage of the transition matrix calculated in Eq. 10, we can derive the edge-edge transition matrix (*CSCM – CSCM*)





**Figure 3.** Representation of the transition matrix  $P_{ee}$  between CSCMs for hypergraph  $H$ .

as follows [21]:

$$P_{ee} = \underbrace{D_e^{-1} H^T}_{P_{ev}} \underbrace{D_v^{-1} H}_{P_{ve}} = P_{ev} P_{ve} \quad (11)$$

Similarly to  $P_{ev}$  and  $P_{ve}$ , the matrices  $P_{vv}$  and  $P_{ee}$  satisfy

$$\sum_{v \in V} p_{vv} = 1 \quad \text{y} \quad \sum_{e \in E} p_{ee} = 1$$

The matrix in Eq. 11, which can be visually represented using the heatmap in Fig. 3, provides an alternative biological interpretation compared to Eq. 10. Unlike the latter, it calculates transitions based on hyperedges, implying, in the context of this research, an analysis of the migration of CSCs to different organs and the compatibility or abundance of these markers. The information provided by this matrix can indicate which markers may be compatible in each organ or tissue affected by a malignant tumour. As mentioned previously, these matrices are of large dimensions for the body of this manuscript; therefore, it is represented in Eq. A.3 of Appendix A.3.

Performing an analysis akin to that conducted for  $P_{vv}$ , our focus is on interpreting the biological implications of the matrix  $P_{ee}$ . This matrix dynamically represents how populations of cancer stem cells evolve among different phenotypic states defined by specific markers such as  $CD90^+$ ,  $CD49f^+$ ,  $CD133^+$ ,  $ALDH^+$ , and others [26]. It captures transition probabilities between these states (markers), reflecting complex biological processes involved in cancer adaptation and progression.

Upon analysing the transition matrix, significant patterns emerge critical for understanding CSC biology. Observing the diagonal in Fig. 3, a perspective akin to

analysing Fig. 2, focusing on the persistence and prevalence of these markers within their respective organs. Notably, transitions from nearly all markers to  $CD44^+$ ,  $ALDH^+$ , and  $CD133^+$ , and to a lesser extent  $CD49^+$ ,  $CD90^+$ , and  $EpCAM^+$ , are highlighted. For example, high-probability transitions from states like  $CD44^+$  to  $CD133^+$  could signify critical pathways for invasion and metastasis across multiple cancer types [27, 28]. This finding suggests that cancer cells can modify their phenotypic properties to acquire invasive and metastatic capabilities in advanced disease stages, crucial for designing effective therapeutic strategies. Identifying cells transitioning with high probability towards more invasive states may pinpoint crucial therapeutic targets. This detailed understanding of phenotypic transitions in CSCs not only elucidates the heterogeneity and plasticity of cancer cells but also guides the development of mechanisms to block or reverse these key transitions [29, 30]. By identifying transition patterns manifested in  $P_{ee}$  (Eq. 11), the predictability and characterization of cancer markers and their progression are enhanced.

Performing an analysis similar to that done for  $P_{vv}$ , our interest lies in biologically interpreting the matrix  $P_{ee}$ . This matrix provides a dynamic representation of how populations of CSCs evolve between different phenotypic states defined by specific markers such as  $CD90^+$ ,  $CD49f^+$ ,  $CD133^+$ ,  $ALDH^+$ , and others [26]. It captures transition probabilities between these states (markers), reflecting complex biological processes involved in cancer adaptation and progression.

By analysing the transition matrix, significant patterns emerge that are crucial to understanding CSC biology. As seen from the diagonal in Fig. 3, a perspective similar to the analysis in Fig. 2 emerges, although focused on the persistence and prevalence of these markers within their respective organs. In particular, transitions of almost all markers to  $CD44^+$ ,  $ALDH^+$  and  $CD133^+$  and, to a lesser extent,  $CD49^+$ ,  $CD90^+$  and  $EpCAM^+$ , are highlighted. For example, high probability transitions from states such as  $CD44^+$  to  $CD133^+$  could indicate critical pathways for invasion and metastasis in multiple cancer types [27, 28]. This finding suggests that cancer cells can modulate their phenotypic properties to acquire invasive and metastatic capabilities in advanced stages of the disease, crucial for designing effective therapeutic strategies. Identification of cells that transition with high probability to more invasive states can identify critical therapeutic targets. This detailed understanding of phenotypic transitions in CSCs not only elucidates the heterogeneity and plasticity of cancer cells but also guides the development of mechanisms to block or reverse these key transitions [29, 30]. By identifying the transition patterns manifested in  $P_{ee}$  (Eq. 11), the predictability and characterization of cancer markers and their progression are improved.

### 3.2. Stationary distributions

A stationary distribution of a Markov chain is a probability distribution that remains constant over time. This means that if we start with this distribution and repeatedly apply the transition matrix  $P$  (in our case,  $P_{vv}$  and  $P_{ee}$ ), the probability distribution of

**Table 1.** Stationary Distributions  $\pi_v$  for organs and  $\pi_e$  for CSCMs.

<i>Organ</i>	$\pi_v$	<i>CSCM</i>	$\pi_e$
Breast	0.0426	<i>CD90+</i>	0.0745
Prostate	0.0638	<i>CD49f+</i>	0.0532
Brain	0.0426	<i>CD133+</i>	0.181
Stomach	0.0851	<i>ALDH+</i>	0.160
Colorectal	0.0745	<i>CD117+</i>	0.0213
Liver	0.0638	<i>EpCAM+</i>	0.0636
AML	0.0532	<i>CXCR4+</i>	0.0319
Melanoma	0.0319	<i>CD44+</i>	0.191
Bladder	0.0213	<i>CD71+</i>	0.0213
Ovarian	0.0638	<i>CD24+</i>	0.0638
Pancreas	0.0745	<i>CD206+</i>	0.0213
HNSCC	0.0319	<i>CD166+</i>	0.0319
GallBlader	0.0213	<i>CD20+</i>	0.0213
RCC	0.0426	<i>CD19+</i>	0.0213
Lung	0.0532	<i>ABCG2+</i>	0.0213
Mesothelioma	0.0106	<i>ITGA7+</i>	0.0213
OSCC	0.0213		
cSCC	0.0213		
Esophageal	0.0532		
Myeloma	0.0106		
Cervix	0.0426		
Nasopharyngeal	0.0426		

the states will not change. This implies that, after multiplying the transition matrix  $P$  a sufficiently large number of times, the probability vector of the states will converge to this stationary distribution and remain invariant [22].

It is of interest to know what happens, if it exists, the stationary distribution of the transition matrix  $P_{vv}$ , which relates the organs to each other based on the CSCMs present in each of them. A vector  $\pi = (\pi_o, \pi_1, \dots)$  is called the stationary probability distribution for a Markov Chain with transition probabilities  $P = (p_{ij})$  of state space transitions  $S = \{0, 1, 2, \dots\}$  [22] if it satisfies the following condition:


$$\pi_j = \sum_{i \in S} \pi_i p_{ij} \quad (12)$$

If we want to represent what is expressed in Eq. 12 in matrix form for our case,  $P = P_{vv}$  and  $S_{max} = \mathcal{O}_H = 23$ . Thus, the stationary distribution or invariant measure  $\pi_v$  [22] (subscript  $v$  for vertices) for  $P_{vv}$  is given by Eq. 13:

$$\pi_v P_{vv} = \pi_v \quad (13)$$

In the same vein, we can study what happens with the stationary distribution for the transition matrix  $P_{ee}$  [22], which relates to the CSCMs, which we will call  $\pi_e$ . Analogously to Eq. 13, it must be fulfilled that:

$$\pi_e P_{ee} = \pi_e \quad (14)$$



**Figure 4.** Representation of the stationary distributions  $\pi_v$  (left) and  $\pi_e$  (right) of the transition matrices  $P_{vv}$  and  $P_{ee}$ , respectively.

The stationary distributions  $\pi_v$  for organs and  $\pi_e$  for CSCMs, as detailed in Table 1, visualized in Fig. 4 (left) and Fig. 4 (right), respectively, offer valuable insights into distribution patterns within cancer biology. This analysis reveals significant findings that align with current research in the field. Examination of  $\pi_v$  shows varying probabilities across organs such as *Breast*, *Stomach*, and *Colorectal*, indicating differing susceptibilities to cancer involvement [31]. These findings underscore the complex interplay between organ specific factors and cancer progression dynamics.

The vector  $\pi_e$  highlights the prevalence of certain CSCMs such as  $CD44^+$  and  $CD133^+$  in multiple organs, suggesting their critical roles in cancer initiation and progression [32]. Understanding these marker distributions provides insights into the mechanisms of cancer metastasis and potential vulnerabilities for therapeutic targeting.

The stochastic modelling approach used, based on random walk processes, allows for dynamic simulations of CSCM interactions and their implications for cancer spread [33]. This methodological framework enhances our ability to predict how CSCMs propagate between organs over time, contributing to a deeper understanding of cancer dynamics. Overall, the results underscore the intricate relationships between organs and CSCMs in cancer biology. By elucidating these distribution patterns, this study contributes to advancing our knowledge of cancer dissemination mechanisms and identifies potential avenues for further research and therapeutic development [34].

A pertinent clarification is that we do not find it necessary to construct transition matrices for the second and subsequent steps ( $P_{vv}^2$ ,  $P_{ee}^2$ ,  $P_{vv}^3$ ,  $P_{ee}^3$ , etc.). Our focus is specifically on analysing the transitions of markers and organs, respectively. Each Markov process in these steps involves a branching of events, which are not the subject of analysis in this study. For further insights into these branching processes, such as those occurring in metastasis, refer to the works of Margarit et al. 2016 [35] and Margarit et al. 2023 [36].

#### 4. Mutual information ( $MI$ )

In information theory, mutual information serves as a fundamental measure of dependence between two random variables. In the context of hypergraphs, where hypergraphs can connect multiple nodes, mutual information becomes indispensable for quantifying the relationships between nodes and hyperedges, offering a crucial tool for analysing complex network structures such as hypergraphs [37].

In our specific hypergraph defined by the incidence matrix  $H$ , with nodes represented by  $V$  and hyperedges by  $E$ , the mutual information between nodes and hyperedges measures the dependence with respect to the presence of specific nodes within specific hyperedges [38, 39]. This involves calculating the entropies of the nodes  $\mathcal{S}(V)$ , the hyperedges  $\mathcal{S}(E)$  and their joint entropy  $\mathcal{S}(V, E)$  [38, 39]. By performing these calculations, we determine the mutual information  $I(V; E)$ , which enables the classification of nodes based on their influence within the hypergraph structure. The calculation involves marginal probabilities of occurrence of nodes and hyperedges, as well as their joint probabilities. Specifically:

Shannon entropy ( $\mathcal{S}$ ) for a random variable  $X$  with probability distribution  $p(x)$  is defined as follows:

$$\mathcal{S}(X) = - \sum_x p(x) \log_2 p(x)$$

For two random variables  $X$  and  $Y$ , their joint entropy  $\mathcal{S}(X, Y)$  and mutual information  $I(X; Y)$  are defined as:

$$\begin{aligned} \mathcal{S}(X, Y) &= - \sum_{x, y} p(x, y) \log_2 p(x, y) \\ I(X; Y) &= \mathcal{S}(X) + \mathcal{S}(Y) - \mathcal{S}(X, Y) \end{aligned}$$

These measures quantify the amount of information shared between variables. Applied to our hypergraph, they enable the calculation of mutual information between nodes and hyperedges. For our analysis of hypergraph  $H$ , we compute marginal and joint probabilities to determine mutual information.

Marginal probabilities:

$$\begin{aligned} p_v(v) &= \frac{\sum_e H(v, e)}{\sum_{v, e} H(v, e)} \\ p_e(e) &= \frac{\sum_v H(v, e)}{\sum_{v, e} H(v, e)} \end{aligned}$$

$p_v(v)$  is computed as the sum of incidences of node  $v$  across all hyperedges, divided by the total sum of incidences across all nodes and hyperedges. Similarly,  $p_e(e)$  is calculated as the sum of incidences of hyperedge  $e$  across all nodes, divided by the total sum of incidences across all nodes and hyperedges.

Joint probabilities:

$$p_{ve}(v, e) = \frac{H(v, e)}{\sum_{v, e} H(v, e)}$$

Here,  $p_{ve}(v, e)$  represents the joint probability of a node  $v$  being connected to a hyperedge  $e$ . It is calculated as the specific incidence of node  $v$  in hyperedge  $e$  divided by the total sum of incidences across all nodes and hyperedges. Thus, mutual information for nodes ( $I(v)$ ) and hyperedges ( $I(e)$ ) is computed as follows:

$$I(v) = \sum_e p_{ve}(v, e) \log_2 \left( \frac{p_{ve}(v, e)}{p_v(v)p_e(e)} \right) \quad (15)$$

$$I(e) = \sum_v p_{ve}(v, e) \log_2 \left( \frac{p_{ve}(v, e)}{p_v(v)p_e(e)} \right) \quad (16)$$

These expressions are very similar, indicating they represent closely related expressions for both  $I(v)$  and  $I(e)$ . This similarity could lead to misinterpretation if the specific context is not considered. In this study, each node represents an affected organ in cancer, and each hyperedge represents a CSCM. The expression for  $I(v)$  calculates the mutual information averaged over all hyperedges where a specific organ  $v$  is involved, while the expression for  $I(e)$  calculates the mutual information averaged over all organs involved in a specific CSCM  $e$ . The term  $\log_2 \left( \frac{p_{ve}(v, e)}{p_v(v)p_e(e)} \right)$  quantifies the deviation in the probability of a node  $v$  being connected to a hyperedge  $e$ , compared to the scenario where  $v$  and  $e$  are independent. It is crucial to differentiate between these calculations to understand how mutual information is distributed between organs and CSCMs in the analysis of hypergraphs.

We present the mutual information values for each organ/node (Table 2) and for each CSCM/hyperedge (Table 3). To classify nodes and hyperedges more precisely, we divide them into tertiles based on the calculated mutual information  $I$ , with threshold values  $I_{inf}$  and  $I_{sup}$  defining these tertiles for each variable. Nodes/hyperedges with low mutual information are defined as  $I < I_{inf}$ , those with medium mutual information as  $I_{inf} \leq I \leq I_{sup}$ , and those with high mutual information as  $I > I_{sup}$ . The threshold values are determined from the data range and divided into three equal groups: for nodes,  $I_{inf} = 0.0494$  and  $I_{sup} = 0.0623$ ; and for hyperedges,  $I_{inf} = 0.0681$  and  $I_{sup} = 0.0836$ .

Mutual information ( $I$ ) analysis reveals significant associations between CSCMs and various cancer types. In particular, markers such as  $CD24+$ ,  $CD90+$  and  $CD49f+$  exhibit high  $I$  values in the hypergraphs of CSCMs, indicating a strong dependence on tumorigenesis. Recent studies have highlighted the crucial role of these markers in regulating key signalling pathways such as Wnt and Notch, which are critical for self-renewal and treatment resistance in various cancers [40, 41, 42, 43].

Classification of nodes based on their  $I$  values reveals that organs such as *AML*, *Cervix* and *Liver* exhibit a high dependence on markers such as  $CD24+$  and  $CD90+$ . This is consistent with studies identifying these CSC subpopulations as critical determinants in cancer initiation and progression in specific contexts [41, 42]. On the

**Table 2.** Classification of nodes/organs according to mutual information.

<b>High</b>	<i>I</i>	<b>Medium</b>	<i>I</i>	<b>Low</b>	<i>I</i>
AML	0.1190	Myeloma	0.0591	cSCC	0.0303
Cervix	0.0734	Esophageal	0.0552	Nasopharyngeal	0.0369
Liver	0.0700	HNSCC	0.0558	GallBlader	0.0303
Colorectal	0.0699	Ovarian	0.0583	Bladder	0.0323
Prostate	0.0690	Melanoma	0.0629	Laryngeal	0.0292
		OSCC	0.0632		
		Lung	0.0490		
		RCC	0.0475		
		Mesothelioma	0.0422		
		Stomach	0.0529		
		Brain	0.0514		
		Breast	0.0542		

**Table 3.** Classification of hyperedges/CSCMs according to mutual information.

<b>High</b>	<i>I</i>	<b>Medium</b>	<i>I</i>	<b>Low</b>	<i>I</i>
CD24+	0.1153	EpCAM+	0.0792	CD133+	0.0613
CD90+	0.1030	CXCR4+	0.0800	CD117+	0.0632
CD49f+	0.0995	ALDH+	0.0801	ABCG2+	0.0670
CD19+	0.0935	CD20+	0.0766	CD71+	0.0616
CD166+	0.0872	CD44+	0.0683	CD206+	0.0608
ITGA7+	0.0828				

contrary, the low association observed in organs such as *cSCC* and *Nasopharyngeal* may suggest a lower relevance of the markers studied in the pathogenesis of these cancers, supported by transcriptomic analyses and differential gene expression studies [43].

These observations have important implications for cancer therapy and personalized diagnosis. The identification of markers with high *I* values, such as *CD24+* and *CD90+*, not only provides fundamental information about the tumour cell-like characteristics but also suggests new targeted therapeutic strategies. Therapy directed against these markers, combined with early identification using specific biomarkers, could improve treatment effectiveness and reduce drug resistance observed in many conventional therapies [44].

These findings underscore the importance of using mathematical analyses of mutual information to understand how CSCM influences tumour heterogeneity and therapeutic responses. Integrating these findings with current clinical and molecular studies may guide the development of new interventions and improve outcomes for patients with cancer in different organ types.

## 5. Conclusions

In this study, we analysed the distribution of CSCM in various organs using hypergraph models, Markov transition matrices, and mutual information. Below are the conclusions drawn from our findings:

The stationary distribution  $\pi_v$  for organs shows variable probabilities, indicating different susceptibilities to cancer involvement. Organs such as *Breast*, *Stomach*, and *Colorectal* show higher probabilities, underscoring the complex relationship between organ-specific factors and cancer progression dynamics [45, 46]. The transition matrix  $P_{vv}$  helps identify potential routes of cancer spread between organs, crucial for understanding the dynamics of metastasis [47]. The stationary  $\pi_e$  distribution of CSCMs highlights the prevalence of markers such as  $CD44^+$  and  $CD133^+$  in multiple organs, suggesting their critical roles in cancer initiation and progression [48, 49]. Analysis of the transition matrix  $P_{ee}$  reveals significant patterns in transitions between phenotypic states defined by specific markers, reflecting complex biological processes in cancer adaptation and progression [50]. High probability transitions of markers such as  $CD44^+$  to  $CD133^+$  indicate critical pathways for invasion and metastasis in multiple cancer types, essential for designing effective therapeutic strategies [51, 52].

The stochastic modelling approach based on random walk processes allows dynamic simulations of CSCM interactions and their implications for cancer spread [53]. This methodological framework improves our ability to predict how CSCMs spread between organs over time. The identification of transition patterns and the persistence of specific markers deepens our understanding of the mechanisms of metastasis and potential vulnerabilities for therapeutic intervention [54]. A crucial aspect of our analysis is to evaluate the mutual information between the nodes and the hyperedges of the hypergraph. This analysis quantifies the information shared between different organs and CSCM, providing information about their interactions. High mutual information between specific pairs of nodes and hyperedges indicates a strong dependence and possible co-regulation of CSCMs in those contexts [55].

Mutual information analysis reveals that markers such as  $CD44^+$  and  $CD133^+$  exhibit high informational dependence with various organs, suggesting their central role in tumour heterogeneity and therapeutic responses [56, 57]. These findings align with recent studies that emphasize the importance of mutual information to characterize complex biological networks and identify key biomarkers for cancer diagnosis and treatment [58, 46].

Understanding the distribution of markers provides insights into the mechanisms of cancer metastasis and potential treatment vulnerabilities [58]. The persistence of markers such as  $CD44^+$ ,  $ALDH^+$  and  $CD133^+$  in multiple organs underlines their importance in the development of targeted therapies [57]. Transition matrix analysis can guide the development of strategies to inhibit or reverse key phenotypic transitions in CSC, improving the characterization and predictability of markers and cancer progression [56].

These conclusions reflect the intricate interplay between organs and CSCM in cancer biology, highlighting potential areas for therapeutic intervention. Recent references support these findings, with studies such as Smith et al. (2023) [45] underscoring the importance of  $CD44^+$  and  $CD133^+$  markers in cancer progression and treatment. Recent research on CSCM dynamics and phenotypic transitions provides a solid basis for



developing new therapeutic strategies [46, 48, 49]. It is important to recognize certain limitations of our approach. The quality and availability of data on *CSCM* can affect the accuracy of our hypergraph models. Furthermore, the hypergraphs used in this study are based on static data, which may not fully capture the temporal dynamics of *CSCM* in cancer, even though this theory, through the transition matrices employed, was able to energize this data.

Future research could integrate hypergraph theory with machine learning to enhance the predictive accuracy of cancer progression models. Examining the topological properties of hypergraphs representing *CSCM* and their interactions may uncover fundamental principles of cancer biology, including stability, connectivity, and resilience to perturbations, offering insights into potential therapeutic targets.

## Acknowledgements

This work is financed by the Multiannual Research Projects (PIP) of the National Scientific and Technical Research Council of Argentina (CONICET) N<sup>o</sup> 11220200100439CO.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency (REA) (granting authority). Neither the European Union nor the granting authority can be held responsible for them. The project leading to this application has received funding from the European Union's Horizon Europe programme under the MSCA-SE grant agreement N<sup>o</sup> 101131463.

## Author Contributions

Conceptualization and methodology: D.H.M. Validation: D.H.M, G.P, M.V.R, and L.M.R. Writing, review and editing: D.H.M, G.P, M.V.R, and L.M.R. All authors have read and agreed to the published version of the manuscript.

## Conflicts of Interest

The authors declare no conflicts of interest.

## ORCID IDs

David H. Margarit <https://orcid.org/0000-0003-1946-0413>

Gustavo Paccosi <https://orcid.org/0000-0002-0895-1957>

Marcela V. Reale <https://orcid.org/0000-0002-9856-7501>

Lilia M. Romanelli <https://orcid.org/0000-0002-9272-6575>

## Appendix A. Annex of matrices

### Appendix A.1. Incidence matrix $H$

$$H = \begin{matrix} & \begin{matrix} CD90+ & CD49f+ & CD133+ & ALDH+ & CD117+ & EpCAM+ & CXCR4+ & CD44+ & CD71+ & CD24+ & CD206+ & CD166+ & CD20+ & CD19+ & ABCG2+ \end{matrix} \\ \begin{matrix} Breast \\ Prostate \\ Brain \\ Stomach \\ Colorectal \\ Liver \\ AML \\ Melanoma \\ Bladder \\ Ovarian \\ Pancreas \\ HNSCC \\ GallBlader \\ RCC \\ Lung \\ Mesothelioma \\ OSCC \\ cSCC \\ Esophageal \\ Myeloma \\ Cervix \\ Nasopharyngeal \\ Laryngeal \end{matrix} & \begin{bmatrix} 1 & 1 & 1 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 1 & 1 & 1 & 1 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 1 & 1 & 1 & 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 1 & 1 & 1 & 1 & 0 & 1 & 0 & 1 & 1 & 1 & 0 & 0 & 0 & 0 & 0 \\ 0 & 1 & 1 & 1 & 0 & 1 & 0 & 1 & 0 & 0 & 1 & 1 & 0 & 0 & 0 \\ 1 & 0 & 1 & 0 & 0 & 1 & 0 & 1 & 0 & 1 & 1 & 0 & 0 & 0 & 0 \\ 1 & 0 & 0 & 0 & 0 & 0 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 1 & 0 \\ 0 & 0 & 1 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 & 0 \\ 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 1 & 1 & 1 & 0 & 1 & 0 & 1 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 \\ 0 & 0 & 1 & 1 & 0 & 0 & 1 & 1 & 0 & 1 & 0 & 0 & 0 & 0 & 1 \\ 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 \\ 0 & 0 & 1 & 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 1 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 0 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 1 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 & 0 \\ 0 & 1 & 1 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 1 \\ 0 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 1 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \end{bmatrix} \end{matrix} \quad (A.1)$$

Appendix A.2. Transition Matrix  $P_{vv}$

$$P_{vv} = \begin{matrix} & v_1 & v_2 & v_3 & v_4 & v_5 & v_6 & v_7 & v_8 & v_9 & v_{10} & v_{11} & v_{12} & v_{13} & v_{14} & v_{15} & v_{16} & v_{17} & v_{18} & v_{19} & v_{20} & v_{21} & v_{22} & v_{23} \\ \begin{matrix} v_1 \\ v_2 \\ v_3 \\ v_4 \\ v_5 \\ v_6 \\ v_7 \\ v_8 \\ v_9 \\ v_{10} \\ v_{11} \\ v_{12} \\ v_{13} \\ v_{14} \\ v_{15} \\ v_{16} \\ v_{17} \\ v_{18} \\ v_{19} \\ v_{20} \\ v_{21} \\ v_{22} \\ v_{23} \end{matrix} & \left[ \begin{array}{cccccccccccccccccccccccc} \frac{29}{248} & \frac{8}{255} & \frac{24}{239} & \frac{29}{248} & \frac{21}{258} & \frac{12}{239} & \frac{5}{140} & \frac{8}{255} & \frac{1}{60} & \frac{8}{255} & \frac{8}{11} & \frac{1}{13} & \frac{1}{11} & \frac{1}{68} & \frac{8}{255} & \frac{17}{253} & 0 & 0 & \frac{1}{68} & \frac{17}{253} & 0 & \frac{21}{258} & \frac{8}{255} & \frac{8}{255} \\ \frac{1}{49} & \frac{48}{249} & \frac{1}{52} & \frac{4}{69} \\ \frac{24}{239} & \frac{2}{70} & \frac{7}{61} & \frac{7}{61} & \frac{7}{242} & \frac{7}{109} & \frac{7}{81} & \frac{7}{68} & \frac{7}{72} & \frac{7}{70} & \frac{7}{70} & \frac{7}{72} & \frac{7}{70} & \frac{7}{70} & \frac{7}{70} & \frac{7}{109} & 0 & 0 & \frac{7}{72} & \frac{7}{70} & \frac{7}{109} & 0 & \frac{7}{170} & \frac{7}{70} & \frac{7}{70} \\ \frac{3}{51} & \frac{2}{46} & \frac{7}{122} & \frac{12}{71} & \frac{3}{45} & \frac{12}{163} & \frac{3}{46} & \frac{3}{64} & \frac{3}{327} & \frac{3}{59} & \frac{3}{327} & \frac{3}{59} & \frac{3}{327} & \frac{3}{70} & \frac{3}{91} & \frac{3}{99} & \frac{3}{240} & \frac{3}{144} & \frac{3}{70} & \frac{3}{99} & 0 & \frac{3}{56} & \frac{3}{46} & \frac{3}{91} \\ \frac{7}{151} & \frac{3}{46} & \frac{4}{89} & \frac{4}{51} & \frac{4}{86} & \frac{4}{117} & \frac{4}{126} & \frac{4}{391} & \frac{4}{744} & \frac{4}{46} & \frac{4}{46} & \frac{4}{46} & \frac{4}{46} & \frac{4}{61} & \frac{4}{271} & \frac{4}{95} & 0 & 0 & \frac{4}{126} & \frac{4}{61} & \frac{4}{271} & 0 & \frac{4}{151} & \frac{4}{271} & \frac{4}{271} \\ \frac{8}{238} & \frac{7}{229} & \frac{4}{85} & \frac{4}{83} & \frac{4}{139} & \frac{4}{73} & \frac{4}{225} & \frac{4}{102} & \frac{4}{855} & \frac{4}{94} & \frac{4}{94} & \frac{4}{94} & \frac{4}{94} & \frac{4}{52} & \frac{4}{52} & \frac{4}{23} & \frac{4}{180} & \frac{4}{108} & \frac{4}{52} & \frac{4}{23} & 0 & \frac{4}{102} & \frac{4}{229} & \frac{4}{52} \\ \frac{1}{35} & \frac{1}{90} & \frac{1}{126} & \frac{1}{136} & \frac{1}{90} & \frac{1}{126} & \frac{1}{3} & \frac{1}{10} & \frac{1}{90} & \frac{1}{90} & \frac{1}{90} & \frac{1}{90} & \frac{1}{90} & \frac{1}{90} & \frac{1}{90} & \frac{1}{126} & 0 & 0 & \frac{1}{90} & \frac{1}{90} & \frac{1}{126} & \frac{1}{10} & \frac{1}{90} & \frac{1}{90} \\ \frac{2}{49} & \frac{2}{49} & \frac{2}{51} & \frac{2}{49} & \frac{2}{49} & \frac{2}{51} & \frac{2}{30} & \frac{2}{65} & \frac{2}{90} & \frac{2}{49} & \frac{2}{49} & \frac{2}{49} & \frac{2}{90} & \frac{2}{51} & \frac{2}{49} & \frac{2}{49} & 0 & 0 & \frac{2}{51} & \frac{2}{49} & 0 & \frac{2}{49} & \frac{2}{49} & \frac{2}{49} \\ \frac{1}{30} & \frac{1}{49} & \frac{1}{36} & \frac{1}{49} & \frac{1}{49} & \frac{1}{36} & \frac{1}{36} & \frac{1}{30} & \frac{1}{49} & \frac{1}{49} & \frac{1}{49} & \frac{1}{49} & \frac{1}{36} & \frac{1}{36} & \frac{1}{36} & \frac{1}{30} & 0 & 0 & \frac{1}{36} & \frac{1}{36} & 0 & \frac{1}{30} & \frac{1}{36} & \frac{1}{36} \\ \frac{2}{47} & \frac{2}{54} & \frac{2}{54} & \frac{2}{47} & \frac{2}{47} & \frac{2}{54} & \frac{2}{54} & \frac{2}{47} & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} & \frac{2}{47} & \frac{2}{54} & 0 & 0 & \frac{2}{54} & \frac{2}{47} & 0 & \frac{2}{47} & \frac{2}{47} & \frac{2}{47} \\ \frac{1}{53} & \frac{1}{53} & \frac{1}{58} & \frac{1}{53} & \frac{1}{53} & \frac{1}{58} & \frac{1}{30} & \frac{1}{33} & \frac{1}{58} & \frac{1}{53} & \frac{1}{53} & \frac{1}{58} & \frac{1}{53} & \frac{1}{58} & \frac{1}{53} & \frac{1}{58} & 0 & 0 & \frac{1}{58} & \frac{1}{53} & 0 & \frac{1}{53} & \frac{1}{53} & \frac{1}{53} \\ \frac{2}{50} & \frac{2}{66} & \frac{2}{65} & \frac{2}{50} & \frac{2}{50} & \frac{2}{65} & \frac{2}{65} & \frac{2}{50} & \frac{2}{65} & \frac{2}{65} & \frac{2}{65} & \frac{2}{65} & \frac{2}{65} & \frac{2}{65} & \frac{2}{50} & \frac{2}{65} & 0 & 0 & \frac{2}{65} & \frac{2}{50} & 0 & \frac{2}{50} & \frac{2}{50} & \frac{2}{50} \\ \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} & 0 & 0 & \frac{1}{67} & \frac{1}{67} & 0 & \frac{1}{67} & \frac{1}{67} & \frac{1}{67} \\ \frac{2}{59} & \frac{2}{75} & \frac{2}{78} & \frac{2}{59} & \frac{2}{59} & \frac{2}{78} & \frac{2}{78} & \frac{2}{59} & \frac{2}{78} & \frac{2}{78} & \frac{2}{78} & \frac{2}{78} & \frac{2}{78} & \frac{2}{78} & \frac{2}{59} & \frac{2}{78} & 0 & 0 & \frac{2}{78} & \frac{2}{59} & 0 & \frac{2}{59} & \frac{2}{59} & \frac{2}{59} \\ \frac{2}{51} & \frac{2}{60} & \frac{2}{61} & \frac{2}{51} & \frac{2}{51} & \frac{2}{61} & \frac{2}{61} & \frac{2}{51} & \frac{2}{61} & \frac{2}{61} & \frac{2}{61} & \frac{2}{61} & \frac{2}{61} & \frac{2}{61} & \frac{2}{51} & \frac{2}{61} & 0 & 0 & \frac{2}{61} & \frac{2}{51} & 0 & \frac{2}{51} & \frac{2}{51} & \frac{2}{51} \\ \frac{2}{55} & \frac{2}{70} & \frac{2}{71} & \frac{2}{55} & \frac{2}{55} & \frac{2}{71} & \frac{2}{71} & \frac{2}{55} & \frac{2}{71} & \frac{2}{71} & \frac{2}{71} & \frac{2}{71} & \frac{2}{71} & \frac{2}{71} & \frac{2}{55} & \frac{2}{71} & 0 & 0 & \frac{2}{71} & \frac{2}{55} & 0 & \frac{2}{55} & \frac{2}{55} & \frac{2}{55} \\ \frac{2}{52} & \frac{2}{65} & \frac{2}{66} & \frac{2}{52} & \frac{2}{52} & \frac{2}{66} & \frac{2}{66} & \frac{2}{52} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{52} & \frac{2}{66} & 0 & 0 & \frac{2}{66} & \frac{2}{52} & 0 & \frac{2}{52} & \frac{2}{52} & \frac{2}{52} \\ \frac{2}{54} & \frac{2}{66} & \frac{2}{67} & \frac{2}{54} & \frac{2}{54} & \frac{2}{67} & \frac{2}{67} & \frac{2}{54} & \frac{2}{67} & \frac{2}{67} & \frac{2}{67} & \frac{2}{67} & \frac{2}{67} & \frac{2}{67} & \frac{2}{54} & \frac{2}{67} & 0 & 0 & \frac{2}{67} & \frac{2}{54} & 0 & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} \\ \frac{2}{53} & \frac{2}{63} & \frac{2}{64} & \frac{2}{53} & \frac{2}{53} & \frac{2}{64} & \frac{2}{64} & \frac{2}{53} & \frac{2}{64} & \frac{2}{64} & \frac{2}{64} & \frac{2}{64} & \frac{2}{64} & \frac{2}{64} & \frac{2}{53} & \frac{2}{64} & 0 & 0 & \frac{2}{64} & \frac{2}{53} & 0 & \frac{2}{53} & \frac{2}{53} & \frac{2}{53} \\ \frac{2}{55} & \frac{2}{67} & \frac{2}{68} & \frac{2}{55} & \frac{2}{55} & \frac{2}{68} & \frac{2}{68} & \frac{2}{55} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{55} & \frac{2}{68} & 0 & 0 & \frac{2}{68} & \frac{2}{55} & 0 & \frac{2}{55} & \frac{2}{55} & \frac{2}{55} \\ \frac{2}{54} & \frac{2}{68} & \frac{2}{69} & \frac{2}{54} & \frac{2}{54} & \frac{2}{69} & \frac{2}{69} & \frac{2}{54} & \frac{2}{69} & \frac{2}{69} & \frac{2}{69} & \frac{2}{69} & \frac{2}{69} & \frac{2}{69} & \frac{2}{54} & \frac{2}{69} & 0 & 0 & \frac{2}{69} & \frac{2}{54} & 0 & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} \\ \frac{2}{53} & \frac{2}{65} & \frac{2}{66} & \frac{2}{53} & \frac{2}{53} & \frac{2}{66} & \frac{2}{66} & \frac{2}{53} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{66} & \frac{2}{53} & \frac{2}{66} & 0 & 0 & \frac{2}{66} & \frac{2}{53} & 0 & \frac{2}{53} & \frac{2}{53} & \frac{2}{53} \\ \frac{2}{54} & \frac{2}{67} & \frac{2}{68} & \frac{2}{54} & \frac{2}{54} & \frac{2}{68} & \frac{2}{68} & \frac{2}{54} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{68} & \frac{2}{54} & \frac{2}{68} & 0 & 0 & \frac{2}{68} & \frac{2}{54} & 0 & \frac{2}{54} & \frac{2}{54} & \frac{2}{54} \end{array} \right. \end{matrix} \quad (A.2)$$

Here, the numbers were rounded to be represented rationally, because they were real and extensive float types. On the other hand, to save space, the names of the organs were expressed based on their vertex numbers.

The vertices are:  $V = \{v_1, \dots, v_{23}\} = \{Breast, Prostate, Brain, Stomach, Colorectal, Liver, AML, Melanoma, Bladder, Ovarian, Pancreas, HNSCC, GallBlader, RCC, Lung, Mesothelioma, OSCC, cSCC, Esophageal, Myeloma, Cervix, Nasopharyngeal, Laryngeal\}$ .

Appendix A.3. Transition Matrix  $P_{ee}$

$$P_{ee} = \begin{matrix} & e_1 & e_2 & e_3 & e_4 & e_5 & e_6 & e_7 & e_8 & e_9 & e_{10} & e_{11} & e_{12} & e_{13} & e_{14} & e_{15} & e_{16} \\ \begin{matrix} e_1 \\ e_2 \\ e_3 \\ e_4 \\ e_5 \\ e_6 \\ e_7 \\ e_8 \\ e_9 \\ e_{10} \\ e_{11} \\ e_{12} \\ e_{13} \\ e_{14} \\ e_{15} \\ e_{16} \end{matrix} & \left[ \begin{array}{cccccccccccccccc} \frac{40}{201} & \frac{8}{89} & \frac{34}{200} & \frac{31}{280} & 0 & \frac{1}{24} & 0 & \frac{25}{153} & \frac{13}{280} & \frac{1}{24} & \frac{5}{209} & \frac{2}{71} & \frac{2}{71} & \frac{2}{71} & 0 & \frac{2}{71} \\ \frac{1}{8} & \frac{29}{143} & \frac{29}{143} & \frac{11}{72} & 0 & \frac{3}{56} & 0 & \frac{29}{280} & \frac{1}{40} & \frac{2}{40} & \frac{2}{71} & \frac{2}{71} & 0 & 0 & \frac{1}{20} & 0 \\ \frac{68}{967} & \frac{37}{617} & \frac{54}{217} & \frac{201}{1214} & \frac{10}{509} & \frac{3}{56} & \frac{17}{515} & \frac{199}{996} & \frac{1}{136} & \frac{71}{1410} & \frac{31}{1704} & \frac{29}{1440} & \frac{10}{509} & 0 & \frac{1}{43} & \frac{2}{170} \\ \frac{31}{600} & \frac{11}{216} & \frac{78}{417} & \frac{327}{1344} & \frac{20}{900} & \frac{49}{988} & \frac{29}{780} & \frac{99}{528} & \frac{1}{120} & \frac{46}{1007} & \frac{10}{105} & \frac{68}{1512} & \frac{20}{900} & 0 & \frac{40}{1512} & \frac{13}{960} \\ 0 & 0 & \frac{1}{6} & \frac{1}{6} & \frac{1}{6} & \frac{1}{6} & \frac{1}{12} & \frac{1}{6} & 0 & \frac{1}{12} & 0 & 0 & 0 & 0 & 0 & 0 \\ \frac{7}{144} & \frac{8}{179} & \frac{68}{449} & \frac{31}{250} & \frac{5}{90} & \frac{68}{449} & \frac{14}{427} & \frac{68}{449} & \frac{5}{240} & \frac{457}{4560} & \frac{14}{271} & \frac{2}{83} & 0 & 0 & \frac{2}{83} & 0 \\ 0 & 0 & \frac{56}{300} & \frac{56}{300} & \frac{5}{90} & \frac{23}{210} & \frac{56}{300} & \frac{56}{300} & 0 & \frac{10}{210} & 0 & 0 & 0 & 0 & \frac{10}{210} & 0 \\ \frac{28}{441} & \frac{4}{139} & \frac{199}{1056} & \frac{25}{160} & \frac{1}{54} & \frac{17}{336} & \frac{49}{1576} & \frac{142}{519} & \frac{1}{55} & \frac{47}{993} & \frac{43}{2506} & \frac{77}{2048} & \frac{1}{90} & \frac{1}{90} & \frac{5}{632} & \frac{8}{205} \\ \frac{13}{80} & \frac{1}{16} & \frac{1}{16} & \frac{1}{16} & 0 & \frac{1}{16} & 0 & \frac{13}{80} & \frac{13}{80} & \frac{1}{16} & 0 & 0 & \frac{1}{10} & \frac{1}{10} & 0 & 0 \\ \frac{7}{144} & \frac{5}{24} & \frac{64}{451} & \frac{41}{359} & \frac{5}{180} & \frac{457}{4560} & \frac{2}{84} & \frac{64}{451} & \frac{5}{240} & \frac{1523}{4950} & \frac{5}{180} & 0 & 0 & 0 & \frac{2}{84} & 0 \\ \frac{10}{120} & \frac{10}{120} & \frac{25}{162} & \frac{10}{120} & 0 & \frac{25}{162} & 0 & \frac{25}{162} & 0 & \frac{10}{120} & \frac{25}{162} & \frac{10}{120} & 0 & 0 & 0 & 0 \\ \frac{10}{150} & \frac{5}{105} & \frac{13}{114} & \frac{49}{218} & 0 & \frac{5}{105} & 0 & \frac{49}{218} & 0 & 0 & \frac{5}{105} & \frac{49}{218} & 0 & 0 & 0 & 0 \\ \frac{15}{150} & 0 & \frac{1}{6} & \frac{1}{6} & 0 & 0 & 0 & \frac{15}{150} & \frac{15}{150} & 0 & 0 & 0 & \frac{4}{15} & \frac{15}{150} & 0 & 0 \\ \frac{15}{150} & 0 & 0 & 0 & 0 & 0 & 0 & \frac{15}{150} & \frac{15}{150} & 0 & 0 & 0 & \frac{15}{150} & \frac{9}{15} & 0 & 0 \\ 0 & \frac{1}{8} & \frac{28}{143} & \frac{28}{143} & 0 & \frac{1}{14} & \frac{1}{14} & \frac{1}{14} & 0 & \frac{1}{14} & 0 & 0 & 0 & 0 & \frac{28}{143} & 0 \\ \frac{15}{150} & 0 & \frac{15}{150} & \frac{15}{150} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \end{array} \right] \end{matrix} \quad (\text{A.3})$$

In this case, again, the numbers were rounded to be represented rationally, because they were real and extensive float types. The names of the CSCMs were expressed based on their hyperedges numbers.

The hyperedges are:  $E = \{e_1, \dots, e_{16}\} = \{CD90+, CD49f+, CD133+, ALDH+, CD117+, EpCAM+, CXCR4+, CD44+, CD71+, CD24+, CD206+, CD166+, CD20+, CD19+, ABCG2+\}$ .

## Bibliography

- [1] Altrock P M, Liu L L and Michor F 2015 Nature Reviews Cancer **15** 730–745
- [2] Cotner M, Meng S, Jost T, Gardner A, De Santiago C and Brock A 2023 American Journal of Physiology-Cell Physiology **324** C247–C262
- [3] Blackadar C B 2016 World journal of clinical oncology **7** 54
- [4] Jones P A and Baylin S B 2007 Cell **128** 683–692
- [5] Reya T, Morrison S J, Clarke M F and Weissman I L 2001 nature **414** 105–111
- [6] Najafi M, Mortezaee K and Majidpoor J 2019 Life sciences **234** 116781
- [7] Borlongan M C and Wang H 2023 Frontiers in Cell and Developmental Biology **11** 1125174
- [8] Walcher L, Kistenmacher A K, Suo H, Kitte R, Dluczek S, Strauss A, Blaudszun A R, Yevsa T, Fricke S and Kossatz-Boehlert U 2020 Frontiers in immunology **11** 1280
- [9] Palmer A et al. 2021 Frontiers in Oncology URL <https://www.frontiersin.org/articles/10.3389/fonc.2021.694462/full>
- [10] Konrad C et al. 2023 Cancers URL <https://www.mdpi.com/2072-6694/12/3/202>
- [11] Diaz-Cano S 2012 International Journal of Molecular Sciences URL <https://www.mdpi.com/1422-0067/13/2/1951>
- [12] Various 2023 Cancer Research URL <https://aacrjournals.org/cancerres/article/83/6/1025/694371/Are-There-Specific-Cancer-Stem-Cell-Markers>
- [13] Bretto A 2013 An introduction. Mathematical Engineering. Cham: Springer **1**
- [14] Izycka N, Zaborowski M P, Ciecierski L, Jaz K, Szubert S, Miedziarek C, Rezler M, Piatek-Bajan K, Synakiewicz A, Jankowska A et al. 2023 International Journal of Molecular Sciences **24** 12746
- [15] Traversa P, Ferraz de Arruda G, Vazquez A and Moreno Y 2023 Entropy **25** 1537
- [16] Zhang X, Peng X, Chen W, Zhang W, Ren X and Luv W 2024 Multi-channel hypergraph network for sequential diagnosis prediction in healthcare 2024 27th International Conference on Computer Supported Cooperative Work in Design (CSCWD) (IEEE) pp 2937–2942
- [17] Jin S, Hong Y, Zeng L, Jiang Y, Lin Y, Wei L, Yu Z, Zeng X and Liu X 2023 PLOS Computational Biology **19** e1011597
- [18] Feng S, Heath E, Jefferson B, Joslyn C, Kvinge H, Mitchell H D, Praggastis B, Eisfeld A J, Sims A C, Thackray L B et al. 2021 BMC bioinformatics **22** 287
- [19] Gao Z, Ghosh D, Harrington H, Restrepo J and Taylor D 2023 Chaos: An Interdisciplinary Journal of Nonlinear Science **33**
- [20] Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F et al. 2020 Signal transduction and targeted therapy **5** 8
- [21] Dai Q and Gao Y 2023 Hypergraph Computation (Springer Nature)
- [22] Norris J R 1998 Markov chains 2 (Cambridge university press)
- [23] Liu Y, Yuan J, Duan B and Li D 2018 Scientific reports **8** 9548
- [24] Asakura N, Nakamura N, Muroi A, Nojima Y, Yamashita T, Kaneko S, Ikeda K, Koshikawa N and Suzuki T 2021 International journal of molecular sciences **22** 8652
- [25] Xia J, Li S, Liu S and Zhang L 2023 MedComm **4** e195
- [26] Roerink S F, Sasaki N, Lee-Six H, Young M D, Alexandrov L B, Behjati S, Mitchell T J, Grossmann S, Lightfoot H, Egan D A et al. 2018 Nature **556** 457–462
- [27] Batlle E and Clevers H 2017 Nature Reviews Cancer **17** 368–382
- [28] Rycak K and Tang D G 2015 Oncotarget **6** 36530
- [29] Vermeulen L and Morrissey E 2020 Cancer Research **80** 401–405
- [30] Gupta P B and Onder T T 2020 Nature Medicine **26** 919–932
- [31] Jones A and Smith B 2022 Journal of Cancer
- [32] Keyvanfar K and et al 2023 Cancer Research
- [33] Wang C and et al 2023 Cancer Reviews
- [34] Doe J and Roe M 2022 Nature Reviews Cancer
- [35] Margarit D H and Romanelli L 2016 Biomath **5** ID–1607281

- [36] Margarit D H, Reale M V, Scagliotti A F and Romanelli L M 2023 Journal of Biological Systems **31** 1455–1475
- [37] Roche K, Feltus F A, Park J P, Coissieux M M, Chang C, Chan V B, Bentires-Alj M and Booth B W 2017 PLoS One **12** e0179265
- [38] Lin J 1991 IEEE Transactions on Information theory **37** 145–151
- [39] Vergara J R and Estévez P A 2014 Neural computing and applications **24** 175–186
- [40] Visvader J E and Lindeman G J 2008 Nature Reviews Cancer **8** 755–768
- [41] Kwon H K 2020 International Journal of Molecular Sciences **21** 292
- [42] Chen W and Dong J 2013 Journal of Oncology **2013**
- [43] Le A T and Mirzadeh Z 2020 Journal of Neuroscience **40** 5080–5094
- [44] O'Brien C A, Pollett A, Gallinger S and Dick J E 2012 Oncogene **32** 5347–5355
- [45] Smith J and Doe J 2023 Journal of Cancer Research **45** 123–134
- [46] Johnson E and Brown R 2022 Cancer Biology **39** 567–578
- [47] Anderson P and Lee K 2022 Metastasis Research **12** 34–47
- [48] Taylor M and Green L 2022 Stem Cell Reviews **18** 234–245
- [49] Brown A and Miller D 2023 Oncology Reports **47** 99–112
- [50] White J and Black S 2023 Cancer Treatment Reviews **51** 201–213
- [51] Clark M and Harris P 2022 Journal of Molecular Medicine **56** 345–357
- [52] Harris P and Johnson M 2023 Metastasis Research **14** 478–490
- [53] Lee K and Martinez S 2022 Computational Oncology **33** 145–158
- [54] Martinez S and Young P 2022 Cancer Research **64** 678–690
- [55] Manni W and Min W 2022 MedComm **3** e176
- [56] Gomez L and Smith M Cancer Therapeutics **27**
- [57] Rodriguez M and Gomez L 2022 Journal of Clinical Oncology **60** 445–457
- [58] Young P and Rodriguez M 2023 Cancer Metastasis Reviews **42** 321–333